Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. develops prescription transdermal pharmaceutical products, with recurring updates centered on its AVERSA abuse-deterrent transdermal technology and a lead abuse-deterrent fentanyl transdermal system. The technology incorporates aversive agents into patches to address abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulant drugs.
Company news also covers product distribution activity for kinesiology tapes and mosquito repellent patches, regulatory and intellectual-property steps tied to transdermal products, shareholder meeting matters, and corporate updates involving operating subsidiaries and Nasdaq-listed common stock and warrants.
Nutriband (NTRB) received a USPTO Notice of Publication for commercial brand name trademarks for its lead abuse-deterrent fentanyl transdermal system, dated September 2, 2026.
The trademarks will appear in the USPTO Trademark Official Gazette, after which a 30‑day opposition period applies before a potential Notice of Allowance. Nutriband plans to secure full intellectual property rights for these commercial brand names in the United States and internationally and to submit the proposed brand name and product labeling to the FDA and other global regulators. The fentanyl patch uses AVERSA™ abuse‑deterrent technology and is projected to have potential peak annual US sales of $80 million to $200 million, supported by patents issued in 46 countries.
Nutriband (NASDAQ:NTRB)/b) announced that CEO and Co-Founder will present in the CEO Spotlight at the 2026 Georgia Life Sciences Summit on August 26, 2026. The Summit, held August 25–26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, convenes leaders from biotechnology, medical technology, research, manufacturing, and investment.
Nutriband (NASDAQ:NTRB) and its Active Intelligence subsidiary will participate in the June 2026 ECRM conference, meeting buyers from Walmart, Walgreens, Amazon, Cardinal Health and other major retailers.
Active Intelligence will showcase its expanding AI Tape line and launch new AI Performance Tape, AI Energy Patches, and AI Sleep products.
Nutriband (NASDAQ:NTRB) announced on April 22, 2026 that CEO and co-founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the US fentanyl/opioid crisis, Nutriband’s AVERSA technology and the company’s opportunity to improve safety for easily abused medications.
The episode is available on YouTube, Spotify, iTunes, Amazon Music and jackneel.com for shareholders and interested parties.
Nutriband (NASDAQ:NTRB) selected a worldwide commercial brand name candidate for its lead product, an abuse‑deterrent fentanyl transdermal system, and will submit the proposed name and labeling to the FDA and other international regulators.
The company also filed for U.S. and international trademark protection, engaged Brand Institute for naming, and cites potential peak U.S. sales of $80M–$200M. The product uses Nutriband’s AVERSA abuse‑deterrent transdermal technology and is covered by patents in 46 countries.
Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health approved its line of kinesiology tapes for import and sale on March 18, 2026. The approval covers the Company’s Kinesiology Line, AVERSA products and mosquito repellent patches.
The Company said its exclusive Costa Rica distributor, Innomedica CCB S.A., oversaw and financed the regulatory approval process. Nutriband and Innomedica plan to begin ramping up marketing and distribution in Costa Rica following this approval.
Nutriband (NASDAQ: NTRB) signed an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA fentanyl (upon approval) and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary.
Innomedica will manage and finance regulatory approvals as products ramp up for launch in Costa Rica.
Nutriband (NASDAQ: NTRB / NTRBW) summarized key points from its Jan 24, 2026 annual shareholder meeting in Orlando. Highlights include board additions, AVERSA™ FENTANYL development progress, patent milestones, manufacturing scale-up, a Type C meeting with the US FDA, planned IND and HAL clinical trial work, ongoing Pocono Pharma sale activity, a FINRA complaint, and 2026 warrant expirations.
Notable specifics: exclusive development partnership with Kindeva, new patents in the US and Macao, collection of $30,000 in closing-extension penalties, and 91,0904 warrants expiring Oct 1, 2026 with $6.43 strike.
Nutriband (NASDAQ:NTRB / NTRBW) CEO Gareth Sheridan published a shareholder letter summarizing 2025 milestones and 2026 outlook. Key 2025 developments include a $5M sale for 90% of the Pocono subsidiary to EarthVision Bio, a 25% preferred stock dividend issued July 25, 2025 (convertible on FDA approval of AVERSA Fentanyl), and USPTO patent issuance No. 12,318,492 on June 3, 2025 covering abuse‑deterrent transdermal systems.
Other items: commercial manufacturing scale‑up completed in June 2025, a Type C meeting with FDA on CMC and pathway to a 505(b)(2) NDA, addition to four Russell indexes, and warrants from the 2021 IPO expiring Oct 1, 2026.